Effects of Iron Chelators on Pulmonary Iron Overload and Oxidative Stress in β-Thalassemic Mice

Pharmacology

Volumn 96, Issue 3-4, 2015, Pages 192-199

  Yatmark, Paranee ^a   Morales, Noppawan Phumala ^a   Chaisri, Urai ^a   Wichaiyo, Surasak ^a   Hemstapat, Warinkarn ^a   Srichairatanakool, Somdet ^b   Svasti, Saovaros ^a   Fucharoen, Suthat ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Alveolar macrophages; Beta knockout mice; Deferiprone; Deferoxamine; Iron overload; Lung pathology; Oxidative stress

Indexed keywords

DEFERIPRONE; DEFEROXAMINE MESYLATE; HEMOGLOBIN BETA CHAIN; IRON DEXTRAN; ANTIDOTE; DEFEROXAMINE; DEXTRAN; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA THALASSEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; IRON CHELATION; IRON OVERLOAD; LIPID PEROXIDATION; LUNG ALVEOLUS MACROPHAGE; LUNG BLOOD VESSEL; LUNG FIBROSIS; LUNG HOMOGENATE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY IRON OVERLOAD; TISSUE INJURY; TREATMENT DURATION; ANIMAL; BETA-THALASSEMIA; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; FIBROSIS; GENETICS; KNOCKOUT MOUSE; LUNG; METABOLISM; PATHOLOGY; RESPIRATORY TRACT MUCOSA;

ANIMALS; ANTIDOTES; BETA-GLOBINS; BETA-THALASSEMIA; DEFEROXAMINE; DEXTRANS; FEMALE; FIBROSIS; IRON CHELATING AGENTS; IRON OVERLOAD; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PYRIDONES; RESPIRATORY MUCOSA;

EID: 84940751400     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000438994     Document Type: Article

References (40)

1. Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P: Pulmonary artery obstruction in thalassaemia. Southeast Asian J Trop Med Public Health 1980; 11: 516-523.
2. Sonakul D, Suwanagool P, Sirivaidyapong P, Fucharoen S: Distribution of pulmonary thromboembolic lesions in thalassemic patients. Birth Defects Orig Artic Ser 1987; 23: 375-384.
3. Keens TG, O'Neal MH, Ortega JA, Hyman CB, Platzker AC: Pulmonary function abnormalities in thalassemia patients on a hypertransfusion program. Pediatrics 1980; 65: 1013-1017.
4. Sohn EY, Noetzli LJ, Gera A, Kato R, Coates TD, Harmatz P, Keens TG, Wood JC: Pulmonary function in thalassaemia major and its correlation with body iron stores. Br J Haematol 2011; 155:102-105.
5. Zakynthinos E, Vassilakopoulos T, Kaltsas P, Malagari E, Daniil Z, Roussos C, Zakynthinos SG: Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax 2001; 56: 737-739.
6. Ooi GC, Khong PL, Lam WK, Trendell-Smith NJ, Tsang KW: Pulmonary iron overload in thalassemia major presenting as small airway disease. Acta Haematol 2002; 108: 43-46.
7. Dimopoulou I, Kremastinos DT, Maris TG, Mavrogeni S, Tzelepis GE: Respiratory function in patients with thalassaemia and iron overload. Eur Respir J 1999; 13: 602-605.
8. Cross CE, Van der Vliet A, O'Neill CA, Louie S, Halliwell B: Oxidants, antioxidants and respiratory tract lining fluids. Environ Health Perspect 1994; 102(suppl 10):185-191.
9. Mateos F, Brock JH, Perez-Arellano JL: Iron metabolism in the lower respiratory tract. Thorax 1998; 53: 594-600.
10. Jamsai D, Zaibak F, Khongnium W, Vadolas J, Voullaire L, Fowler KJ, Gazeas S, Fucharoen S, Williamson R, Ioannou PA: A humanized mouse model for a common beta0-thalassemia mutation. Genomics 2005; 85: 453-461.
11. Moon SN, Han JW, Hwang HS, Kim MJ, Lee SJ, Lee JY, Oh CK, Jeong DC: Establishment of secondary iron overloaded mouse model: evaluation of cardiac function and analysis according to iron concentration. Pediatr Cardiol 2011; 32: 947-952.
12. Yatmark P, Morales NP, Chaisri U, Wichaiyo S, Hemstapat W, Srichairatanakool S, Svasti S, Fucharoen S: Iron distribution and histopathological characterization of the liver and heart of ?-thalassemic mice with parenteral iron overload: effects of deferoxamine and deferiprone. Exp Toxicol Pathol 2014; 66: 333-343.
13. Nandedkar SD, Feroah TR, Hutchins W, Weihrauch D, Konduri KS, Wang J, Strunk RC, DeBaun MR, Hillery CA, Pritchard KA: Histopathology of experimentally induced asthma in a murine model of sickle cell disease. Blood 2008; 112: 2529-2538.
14. Foy AL, Williams HL, Cortell S, Conrad ME: A modified procedure for the determination of non-heme iron in tissue. Anal Biochem 1967; 18: 559-563.
15. Asakawa T, Matsushita S: Coloring conditions of thiobarbituric acid test for detecting lipid hydroperoxides. Lipids 1980; 15: 137-140.
16. Morales NP, Yamaguchi Y, Murakami K, Kosem N, Utsumi H: Hepatic reduction of carbamoyl-PROXYL in ferric nitrilotriacetate induced iron overloaded mice: An in vivo ESR study. Biol Pharm Bull 2012; 35: 1035-1040.
17. Rahman I, Kode A, Biswas SK: Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006; 1: 3159-3165.
18. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
19. Aebi H: Catalase in vitro. Methods Enzymol 1984; 105: 121-126.
20. Rund D, Rachmilewitz E: Beta-thalassemia. N Engl J Med 2005; 353: 1135-1146.
21. Barnett CF, Hsue PY, Machado RF: Pulmonary hypertension: An increasing recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 2008; 23: 324-331.
22. Quinlan GJ, Evans TW, Gutteridge JM: Iron and the redox status of the lungs. Free Radic Biol Med 2002; 33: 1306-1313.
23. Persson HL, Richardson DR: Iron-binding drugs targeted to lysosomes: A potential strategy to treat inflammatory lung disorders. Expert Opin Investig Drugs 2005; 14: 997-1008.
24. Cooper DM, Mansell AL, Weiner MA, Berdon WE, Chetty-Baktaviziam A, Reid L, Mellins RB: Low lung capacity and hypoxemia in children with thalassemia major. Am Rev Respir Dis 1980; 121: 639-646.
25. Grisaru D, Rachmilewitz EA, Mosseri M, Gotsman M, Lafair JS, Okon E, Goldfarb A, Hasin Y: Cardiopulmonary assessment in beta-thalassemia major. Chest 1990; 98: 1138-1142.
26. Hershko C: Oral iron chelators: new opportunities and new dilemmas. Haematologica 2006; 91: 1307-1312.
27. Kontoghiorghes GJ, Neocleous K, Kolnagou A: Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003; 8: 553-584.
28. Corhay JL, Weber G, Bury T, Mariz S, Roelandts I, Radermecker MF: Iron content in human alveolar macrophages. Eur Respir J 1992; 5: 804-809.
29. Turi JL, Yang F, Garrick MD, Piantadosi CA, Ghio AJ: The iron cycle and oxidative stress in the lung. Free Radic Biol Med 2004; 36: 850-857.
30. Gutteridge JM, Mumby S, Quinlan GJ, Chung KF, Evans TW: Pro-oxidant iron is present in human pulmonary epithelial lining fluid: implications for oxidative stress in the lung. Biochem Biophys Res Commun 1996; 220: 1024-1027.
31. Hiraiwa K, van Eeden SF: Contribution of lung macrophages to the inflammatory responses induced by exposure to air pollutants. Mediators Inflamm 2013; 2013: 619523.
32. Ward RJ, Wilmet S, Legssyer R, Crichton RR: The influence of iron homoeostasis on macrophage function. Biochem Soc Trans 2002; 30: 762-765.
33. Legssyer R, Josse C, Piette J, Ward RJ, Crichton RR: Changes in function of iron-loaded alveolar macrophages after in vivo administration of desferrioxamine and/or chloroquine. J Inorg Biochem 2003; 94: 36-42.
34. Wang L, Harrington L, Trebicka E, Shi HN, Kagan JC, Hong CC, Lin HY, Babitt JL, Cherayil BJ: Selective modulation of TLR4-activated inflammatory responses by altered iron homeostasis in mice. J Clin Invest 2009; 11: 3322-3326.
35. Le BV, Khorsi-Cauet H, Bach V, Gay-Queheillard J: Modulation of Pseudomonas aeruginosa lipopolysaccharide-induced lung inflammation by chronic iron overload in rat. FEMS Immunol Med Microbiol 2012; 64: 255-264.
36. Salama SA, Omar HA, Maghrabi IA, AlSaeed MS, El-Tarras AE: Iron supplementation at high altitudes induces inflammation and oxidative injury to lung tissues in rats. Toxicol Appl Pharmacol 2014; 274: 1-6.
37. Vento S, Cainelli F, Cesario F: Infections and thalassaemia. Lancet Infect Dis 2006; 6: 226-233.
38. Zhu S, Manuel M, Tanaka S, Choe N, Kagan E, Matalon S: Contribution of reactive oxygen and nitrogen species to particulate-induced lung injury. Environ Health Perspect 1998; 106(suppl 5):1157-1163.
39. Morel I, Cillard J, Lescoat G, Sergent O, Pasdeloup N, Ocaktan AZ, Abdallah MA, Brissot P, Cillard P: Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in ironloaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine. Free Radic Biol Med 1992; 13: 499-508.
40. Morel I, Sergent O, Cogrel P, Lescoat G, Pasdeloup N, Brissot P, Cillard P, Cillard J: EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine. Free Radic Biol Med 1995; 18: 303-310.